193 related articles for article (PubMed ID: 38617633)
1. Deciphering the Impact of Rare Missense Variants in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer through Whole Exome Sequencing: A Computational Approach.
Balasundaram A; C Doss GP
ACS Omega; 2024 Apr; 9(14):16288-16302. PubMed ID: 38617633
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
Yao Y; Yang H; Zhu B; Wang S; Pang J; Wu X; Xu Y; Zhang J; Zhang J; Ou Q; Tian H; Zhao Z
Respir Res; 2023 Jan; 24(1):28. PubMed ID: 36698189
[TBL] [Abstract][Full Text] [Related]
3. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
4. Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis.
Mehta A; Vasudevan S
Cancer Treat Res Commun; 2021; 28():100398. PubMed ID: 34052672
[TBL] [Abstract][Full Text] [Related]
5. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
[TBL] [Abstract][Full Text] [Related]
6. Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review.
Liu L; Wang C; Li S; Bai H; Wang J
Transl Lung Cancer Res; 2021 Sep; 10(9):3823-3839. PubMed ID: 34733631
[TBL] [Abstract][Full Text] [Related]
7. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
8. Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors.
Menzel M; Kirchner M; Kluck K; Ball M; Beck S; Allgäuer M; Assmann C; Schnorbach J; Volckmar AL; Tay TKY; Goldschmid H; Tan DS; Thomas M; Kazdal D; Budczies J; Stenzinger A; Christopoulos P
J Pathol Clin Res; 2024 Mar; 10(2):e354. PubMed ID: 38284983
[TBL] [Abstract][Full Text] [Related]
9. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
10. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).
Lim SM; Kim HR; Cho EK; Min YJ; Ahn JS; Ahn MJ; Park K; Cho BC; Lee JH; Jeong HC; Kim EK; Kim JH
Oncotarget; 2016 Jun; 7(24):36311-36320. PubMed ID: 27121209
[TBL] [Abstract][Full Text] [Related]
11. Strategies to Improve Outcomes of Patients with EGRF-Mutant Non-Small Cell Lung Cancer: Review of the Literature.
Zhou C; Yao LD
J Thorac Oncol; 2016 Feb; 11(2):174-86. PubMed ID: 26845114
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
Su KY; Chen HY; Li KC; Kuo ML; Yang JC; Chan WK; Ho BC; Chang GC; Shih JY; Yu SL; Yang PC
J Clin Oncol; 2012 Feb; 30(4):433-40. PubMed ID: 22215752
[TBL] [Abstract][Full Text] [Related]
13. The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in
Wang Z; Zhang L; Xu W; Li J; Liu Y; Zeng X; Zhong M; Zhu Y
J Inflamm Res; 2022; 15():649-667. PubMed ID: 35140497
[TBL] [Abstract][Full Text] [Related]
14. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
15. Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genes.
Kumar S U; Balasundaram A; Cathryn R H; Varghese RP; R S; R G; Younes S; Zayed H; Doss C GP
Comput Biol Med; 2022 Sep; 148():105701. PubMed ID: 35753820
[TBL] [Abstract][Full Text] [Related]
16. Overall signature of acquired KRAS gene changes in advanced non-small cell lung cancer patient with EGFR-TKI resistance.
Zheng J; Dou Y; Huang D; Wang Y; Han R; Hu C; Zhu M; Lu C; Lin C; Wu D; Liu Y; Tang H; He T; Jiang W; He Y
Jpn J Clin Oncol; 2024 Jan; 54(1):89-96. PubMed ID: 37721193
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer.
Fang Y; Wang Y; Zeng D; Zhi S; Shu T; Huang N; Zheng S; Wu J; Liu Y; Huang G; Xue Y; Bin J; Liao Y; Shi M; Liao W
Oncoimmunology; 2021; 10(1):1951019. PubMed ID: 34345533
[TBL] [Abstract][Full Text] [Related]
18. Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer.
Wang TH; Wu CC; Huang KY; Leu YL; Yang SC; Chen CL; Chen CY
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396393
[TBL] [Abstract][Full Text] [Related]
19. Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer.
Osude C; Lin L; Patel M; Eckburg A; Berei J; Kuckovic A; Dube N; Rastogi A; Gautam S; Smith TJ; Sreenivassappa SB; Puri N
Cells; 2022 May; 11(10):. PubMed ID: 35626731
[TBL] [Abstract][Full Text] [Related]
20. PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy.
Fang W; Huang Y; Gu W; Gan J; Wang W; Zhang S; Wang K; Zhan J; Yang Y; Huang Y; Zhao H; Zhang L
Transl Lung Cancer Res; 2020 Aug; 9(4):1258-1267. PubMed ID: 32953503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
